Incidence and antimicrobial profile of extended-spectrum β-lactamase producing gram-negative bacterial isolates: An in-vitro and statistical analysis

Dawoud, Turki M.; Syed, Asad; Maurya, Amit Kumar; Ahmad, Syed Sayeed; Rabbani, Quazzafi; Alyousef, Abdullah A.; Alqasim, Abdulaziz; Arshad, Muhammad; Khan, Mohd Sajid; Khalid, Mohammad; Khan, Haroon; Daglia, Maria

doi:10.1016/j.jiph.2020.06.026

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression can be constitutive or induced, either through direct sensing of the BL warhead (via acylation) or indirect sensing of cell wall damage (via muropeptides and other peptidoglycan fragments) . Genes encoding these resistance enzymes can either be chromosomally encoded or transferred between organisms through mobile genetic elements, such as plasmids and transposons, which significantly contribute to the spread and overall success of BLase-mediated resistance. , BLase expression is the most significant resistance mechanism for Gram-negative infections, and BLase-mediated resistance continues to accelerate globally: rates of blaZ expression in staphylococci have increased from less than 20% in the 1940s to greater than 85% today; TEM-1, a plasmid-encoded Ambler class A BLase, is found in 70% of Enterobacteriaceae infections; and extended-spectrum β-lactamases (ESBLs) such as CTX-M, which hydrolyze most penicillins and later-generation (oxyimino) cephalosporins and are resistant to conventional β-lactamase inhibitors (BLIs), are found in nearly 40% of Gram-negative infections. , This alarming rise in BLase expression underscores the need for novel approaches capable of identifying, studying, and selectively targeting these resistant organisms.…”

Section: Introduction To β-Lactams and β-Lactamasesmentioning

confidence: 99%

“…9,10 BLase expression is the most significant resistance mechanism for Gram-negative infections, and BLase-mediated resistance continues to accelerate globally: rates of blaZ expression in staphylococci have increased from less than 20% in the 1940s to greater than 85% today; 12 TEM-1, a plasmid-encoded Ambler class A BLase, is found in 70% of Enterobacteriaceae infections; 12 and extended-spectrum β-lactamases (ESBLs) such as CTX-M, which hydrolyze most penicillins and latergeneration (oxyimino) cephalosporins and are resistant to conventional β-lactamase inhibitors (BLIs), are found in nearly 40% of Gram-negative infections. 13,14 This alarming rise in BLase expression underscores the need for novel approaches capable of identifying, studying, and selectively targeting these resistant organisms.…”

Section: Introduction To β-Lactams and β-Lactamasesmentioning

confidence: 99%

See 1 more Smart Citation

β-Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design

2022

View full text Add to dashboard Cite

The discovery of β-lactam (BL) antibiotics in the early 20th century represented a remarkable advancement in human medicine, allowing for the widespread treatment of infectious diseases that had plagued humanity throughout history. Yet, this triumph was followed closely by the emergence of β-lactamase (BLase), a bacterial weapon to destroy BLs. BLase production is a primary mechanism of resistance to BL antibiotics, and the spread of new homologues with expanded hydrolytic activity represents a pressing threat to global health. Nonetheless, researchers have developed strategies that take advantage of this defense mechanism, exploiting BLase activity in the creation of probes, diagnostic tools, and even novel antibiotics selective for resistant organisms. Early discoveries in the 1960s and 1970s demonstrating that certain BLs expel a leaving group upon BLase cleavage have spawned an entire field dedicated to employing this selective release mechanism, termed BLase-mediated fragmentation. Chemical probes have been developed for imaging and studying BLase-expressing organisms in the laboratory and diagnosing BL-resistant infections in the clinic. Perhaps most promising, new antibiotics have been developed that use BLase-mediated fragmentation to selectively release cytotoxic chemical "warheads" at the site of infection, reducing offtarget effects and allowing for the repurposing of putative antibiotics against resistant organisms. This Review will provide some historical background to the emergence of this field and highlight some exciting recent reports that demonstrate the promise of this unique release mechanism.

show abstract

Section: Introduction To β-Lactams and β-Lactamasesmentioning

confidence: 99%

Section: Introduction To β-Lactams and β-Lactamasesmentioning

confidence: 99%

β-Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design

2022

View full text Add to dashboard Cite

show abstract

Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010–2020 decade in India

Kharat,

Makwana,

Nasser

et al. 2024

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems

Gandra

Takahashi

Mitrani-Gold

et al. 2022

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Background Antimicrobial resistance is an urgent global healthcare concern. Beyond carbapenems as broad-spectrum, often ‘last resort’ antibiotics, oral penem antibiotics currently are approved only in Japan and India, used for the treatment of indications including urinary tract infections (UTIs). Exploring oral penem use to better understand the impact of antibiotic resistance on public health would help inform the management of infectious diseases, including UTIs. Scoping Review Methodology This scoping review investigated the impact of faropenem and other oral penems on Enterobacterales infection treatment and evaluated evidence for faropenem resistance and cross-resistance to carbapenems. PubMed, Embase, J-STAGE and CiNii were searched for relevant English- or Japanese-language articles published between 1 January 1996 and 6 August 2021. Key Findings From 705 unique publications, 29 eligible articles were included (16 in vitro studies; 10 clinical trials; 2 in vitro and in vivo studies; and 1 retrospective medical chart review). Limited evidence described faropenem to treat infectious disease; only four randomized clinical trials were identified. Faropenem dosing regimens varied broadly within and between indications. One study indicated potential dependence of penem efficacy on underlying antibiotic resistance mechanisms, while several studies reported UTI persistence or recurrence after faropenem treatment. In vitro MIC data suggested some potential bacterial resistance to faropenem, while limited clinical data showed resistance emergence after faropenem treatment. Preliminary in vitro evidence suggested faropenem resistance might foster cross-resistance to carbapenems. Overall, very limited clinical evidence describes faropenem for treating infectious diseases. Preclinical and clinical research investment and dedicated community surveillance monitoring is crucial for understanding faropenem treatment patterns, resistance and potential cross-resistance to carbapenems.

show abstract

Incidence and antimicrobial profile of extended-spectrum β-lactamase producing gram-negative bacterial isolates: An in-vitro and statistical analysis

Cited by 4 publications

References 30 publications

β-Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design

β-Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design

Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010–2020 decade in India

A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems

Contact Info

Product

Resources

About